Latest news with #Celgene
Globe and Mail
25-06-2025
- Business
- Globe and Mail
Relapsing-Remitting Multiple Sclerosis Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Relapsing-Remitting Multiple Sclerosis Pipeline Insight 2025' report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Relapsing-Remitting Multiple Sclerosis pipeline landscape. It covers the Relapsing-Remitting Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Relapsing-Remitting Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Relapsing-Remitting Multiple Sclerosis Pipeline Report to explore emerging therapies, key Relapsing-Remitting Multiple Sclerosis Companies, and future Relapsing-Remitting Multiple Sclerosis treatment landscapes @ Relapsing-Remitting Multiple Sclerosis Pipeline Outlook Report Key Takeaways from the Relapsing-Remitting Multiple Sclerosis Pipeline Report In June 2025, Novartis Pharmaceuticals announced a study will evaluate if relapsing-remitting MS patients that have not had a relapse in the past year would benefit from a switch to ofatumumab versus staying on their continued current therapy. This study will also look at whether an elevated serum neurofilament light (NfL) level predicts enhanced benefit from a switch to ofatumumab. In June 2025, Celgene conducted a study is to evaluate the effectiveness, safety, tolerability, drug levels and drug effects of ozanimod compared to fingolimod in children and adolescents with relapsing remitting multiple sclerosis (RRMS). DelveInsight's Relapsing-Remitting Multiple Sclerosis pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Relapsing-Remitting Multiple Sclerosis treatment. The leading Relapsing-Remitting Multiple Sclerosis Companies such as Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others. Promising Relapsing-Remitting Multiple Sclerosis Therapies such as TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others. Discover how the Relapsing-Remitting Multiple Sclerosis treatment paradigm is evolving. Access DelveInsight's in-depth Relapsing-Remitting Multiple Sclerosis Pipeline Analysis for a closer look at promising breakthroughs @ Relapsing-Remitting Multiple Sclerosis Clinical Trials and Studies Relapsing-Remitting Multiple Sclerosis Emerging Drugs Profile IMU-838: Immunic AG Vidofludimus calcium is an orally administered investigational small molecule drug being developed for chronic inflammatory and autoimmune diseases, currently in late-stage clinical trials for multiple sclerosis (MS). Uniquely, vidofludimus calcium's first-in-class, dual mode of action combines neuroprotective, anti-inflammatory and anti-viral effects to target the complex pathophysiology of MS. As a selective immune modulator, it activates the neuroprotective transcription factor, nuclear receptor-related 1 (Nurr1), which provides direct and indirect neuroprotective effects. Additionally, vidofludimus calcium achieves anti-inflammatory and anti-viral effects through highly selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). Currently, the drug is in Phase III stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis. IMCY-0141: Imcyse SA IMCY-0141 Imotope™ is designed based on MOG (Myelin Oligodendrocyte Glycoprotein) with the aim to halt the progression of multiple sclerosis (MS) by stopping the body's immune system from attacking the central nervous system and disrupting undesirable autoimmune responses that drive the destruction of the myelin sheath protecting the nerves. IMCY-0141 has shown promising results in several MS preclinical models, demonstrating an immune response that supports the proposed mode of action and inducing a memory response so that the treatment effect is long-lasting and requires less frequent dosing regimens. Also, if treatment is begun early enough, it has the potential to allow patients to live with minimal impact from the disease. Currently, the drug is in Phase I/II stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis. ANK-700: Anokion SA ANK-700 is an investigational therapy developed by Anokion for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS). It employs a novel approach known as an ""inverse vaccine,"" aiming to re-educate the immune system to recognize specific myelin proteins as ""self,"" thereby preventing autoimmune attacks on the central nervous system. This strategy seeks to reduce neuroinflammation while preserving overall immune function. Anokion's approach utilizes its proprietary immune tolerance platform, which targets natural pathways in the liver to restore immune tolerance. This liver-targeted antigen strategy effectively expands antigen-specific regulatory T-cells in vivo, offering therapeutic potential across various inflammatory conditions, including multiple sclerosis. ANK-700's innovative mechanism and encouraging early clinical data position it as a promising candidate for future disease-modifying therapies in RRMS. Currently, the drug is in Phase I stage of its development for the treatment of Relapsing-Remitting Multiple Sclerosis. The Relapsing-Remitting Multiple Sclerosis pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Relapsing-Remitting Multiple Sclerosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Relapsing-Remitting Multiple Sclerosis Treatment. Relapsing-Remitting Multiple Sclerosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Relapsing-Remitting Multiple Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Relapsing-Remitting Multiple Sclerosis market. Get a detailed analysis of the latest innovations in the Relapsing-Remitting Multiple Sclerosis pipeline. Explore DelveInsight's expert-driven report today! @ Relapsing-Remitting Multiple Sclerosis Unmet Needs Relapsing-Remitting Multiple Sclerosis Companies Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others. Relapsing Remitting multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Relapsing-Remitting Multiple Sclerosis Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Relapsing-Remitting Multiple Sclerosis Therapies and key Relapsing-Remitting Multiple Sclerosis Developments @ Relapsing-Remitting Multiple Sclerosis Market Drivers and Barriers, and Future Perspectives Scope of the Relapsing-Remitting Multiple Sclerosis Pipeline Report Coverage- Global Relapsing-Remitting Multiple Sclerosis Companies- Immunic AG, Sanofi, Anokion, RemeGen, HuniLife Biotechnology, Biogen, Clene Nanomedicine, Novartis, Celltrion, Imcyse SA, Takeda and others. Relapsing-Remitting Multiple Sclerosis Therapies- TMP001, Rebif®, Avonex®, dimethyl fumarate, BAF312, IMCY-0141, Ocrelizumab, and others. Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Relapsing-Remitting Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Relapsing-Remitting Multiple Sclerosis drug development? Find out in DelveInsight's exclusive Relapsing-Remitting Multiple Sclerosis Pipeline Report—access it now! @ Relapsing-Remitting Multiple Sclerosis Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Relapsing-Remitting Multiple Sclerosis: Overview Pipeline Therapeutics Therapeutic Assessment Relapsing-Remitting Multiple Sclerosis– DelveInsight's Analytical Perspective Late Stage Products (Phase III) IMU-838: Immunic AG Drug profiles in the detailed report….. Mid Stage Products (Phase II) Telitacicept: RemeGen Drug profiles in the detailed report….. Early Stage Products (Phase I) ANK700: Anokion Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Relapsing-Remitting Multiple Sclerosis Key Companies Relapsing-Remitting Multiple Sclerosis Key Products Relapsing-Remitting Multiple Sclerosis- Unmet Needs Relapsing-Remitting Multiple Sclerosis- Market Drivers and Barriers Relapsing-Remitting Multiple Sclerosis- Future Perspectives and Conclusion Relapsing-Remitting Multiple Sclerosis Analyst Views Relapsing-Remitting Multiple Sclerosis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
CNBC
24-06-2025
- Business
- CNBC
Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug
Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it could retain a monopoly. In a complaint filed in Manhattan federal court, Cigna said Bristol Myers' Celgene unit filed sham lawsuits to protect its patents for Pomalyst, whose chemical name is pomalidomide, and paid off several generic drugmakers to end legal challenges. The insurer also said Celgene did nottell the U.S. Patent and Trademark Office that a Boston doctor had obtained a patent for pomalidomide to treat multiple myeloma, and defrauded that office by claiming "unexpected" positive results in testing. By having "willfully maintained monopoly power" over brand name and generic Pomalyst, Bristol Myers caused purchasers such as Cigna to overpay by "many hundreds of millions, if not billions, of dollars," the complaint said. Bristol Myers, based in Princeton, New Jersey, did not immediately respond to requests for comment. Cigna, based in Bloomfield, Connecticut, is seeking unspecified triple damages. It sued nearly three months after a Manhattan federal judge dismissed a proposed class action led by Blue Cross Blue Shield of Louisiana raising similar claims. In that case, U.S. District Judge Edgardo Ramos said the plaintiffs failed to show Celgene committed fraud in procuring patents for Pomalyst, or that Celgene filed baseless lawsuits against generic drugmakers that led to fraudulent settlements. Bristol Myers' U.S. sales of the drug, which is also sold under the name Imnovid, totaled $2.7 billion last year and $537 million in the first three months of 2025. Multiple myeloma is a blood cancer that affects plasma cells in bone marrow. There is no known cure, and the five-year survival rate was 62.4% between 2015 and 2021, according to the National Cancer Institute.
Reuters
24-06-2025
- Business
- Reuters
Cigna sues Bristol Myers over alleged monopoly for multiple myeloma drug Pomalyst
NEW YORK, June 24 (Reuters) - Cigna (CI.N), opens new tab sued Bristol Myers (BMY.N), opens new tab on Tuesday, accusing the drugmaker of violating federal antitrust law by maintaining a monopoly over a blockbuster multiple myeloma drug sold under the brand name Pomalyst. The insurer said Bristol Myers and its Celgene unit have delayed generic versions of Pomalyst from entering the market, causing Cigna and other purchasers to overpay by hundreds of millions, and perhaps billions, of dollars. Cigna filed its lawsuit in Manhattan federal court.
Globe and Mail
15-05-2025
- Business
- Globe and Mail
Hodgkin's Lymphoma Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Hodgkin's Lymphoma Pipeline Insight 2025' report provides comprehensive insights about 15+ companies and 20+ pipeline drugs in Hodgkin's Lymphoma pipeline landscape. It covers the Hodgkin's Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hodgkin's Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Hodgkin's Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Hodgkin's Lymphoma Pipeline Outlook Key Takeaways from the Hodgkin's Lymphoma Pipeline Report In May 2025, Celgene announced a phase II study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. In May 2025, Hoffmann-La Roche conducted a Phase I/II study designed to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of a novel T-Cell bispecific (TCB), glofitamab, administered by intravenous (IV) infusion as a single agent and in combination with obinutuzumab, following pre-treatment with a one-time, fixed dose of obinutuzumab. In May 2025, Bristol-Myers Squibb organized a study is to assess the safety, tolerability, drug levels, and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma. DelveInsight's Hodgkin's Lymphoma Pipeline report depicts a robust space with 15+ active players working to develop 20+ pipeline therapies for Hodgkin's Lymphoma treatment. The leading Hodgkin's Lymphoma Companies such as Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others. Promising Hodgkin's Lymphoma Pipeline Therapies such as HCD122, Resminostat (4SC-201), Ruxolitinib, AK105, ITF2357, Panobinostat, Obatoclax mesylate (GX15-070MS) and others. Stay ahead with the most recent pipeline outlook for Hodgkin's Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Hodgkin's Lymphoma Treatment Drugs Hodgkin's Lymphoma Emerging Drugs Profile AFM 13: Affimed Therapeutics AFM13 is a first-in-class innate cell engager (ICE®) that uniquely activates the innate immune system to destroy CD30-positive hematologic tumors. AFM13 induces specific and selective killing of CD30-positive tumor cells, leveraging the power of the innate immune system by engaging and activating natural killer (NK) cells and macrophages. AFM13 is most advanced ICE® clinical program and was evaluated as monotherapy in a Phase IIB trial in patients with relapsed/refractory peripheral T cell lymphoma (REDIRECT). The study achieved an ORR of 32.4% demonstrating anti-tumor activity with a DOR of 2.3 months and a well-managed safety profile. AFM13 is a tetravalent bispecific innate cell engager designed to act as a bridge between the innate immune cells and the tumor creating the necessary proximity for the innate immune cells to specifically destroy the tumor cells. Currently it is in Phase II stage of clinical trial evaluation to treat Hodgkin's Lymphoma. AUR105 : Aurigene Oncology AUR105 is a small molecule that acts by targeting protein arginine methyltransferase 5 (PRMT5). The drug candidate is also under development for other indications like solid tumor, non-Hodgkin lymphoma, leukemia or Hodgkin lymphoma. The drug candidate is administered through oral route. Currently the drug is being evaluated in Phase I for the treatment of Hodgkin's Lymphoma. The Hodgkin's Lymphoma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Hodgkin's Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hodgkin's Lymphoma Treatment. Hodgkin's Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Hodgkin's Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hodgkin's Lymphoma market Explore groundbreaking therapies and clinical trials in the Hodgkin's Lymphoma Pipeline. Access DelveInsight's detailed report now! @ New Hodgkin's Lymphoma Drugs Hodgkin's Lymphoma Companies Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others. Hodgkin's Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral intravenous Subcutaneous Topical Hodgkin's Lymphoma Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Unveil the future of Hodgkin's Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Hodgkin's Lymphoma Market Drivers and Barriers Scope of the Hodgkin's Lymphoma Pipeline Report Coverage- Global Hodgkin's Lymphoma Companies- Merck Sharp & Dohme LLC, Affimed Therapeutics, Aurigene Oncology, AstraZeneca, Novartis Pharmaceuticals, Bristol-Myers Squibb, Italfarmaco, ADC Therapeutics and others. Hodgkin's Lymphoma Pipeline Therapies- HCD122, Resminostat (4SC-201), Ruxolitinib, AK105, ITF2357, Panobinostat, Obatoclax mesylate (GX15-070MS) and others. Hodgkin's Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Hodgkin's Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Hodgkin's Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hodgkin's Lymphoma Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Hodgkin's Lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Hodgkin's Lymphoma – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug Name: Company Name Drug profiles in the detailed report….. Mid-Stage Products (Phase II) AFM13: Affimed Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) AUR105 : Aurigene Oncology Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Hodgkin's Lymphoma Key Companies Hodgkin's Lymphoma Key Products Hodgkin's Lymphoma- Unmet Needs Hodgkin's Lymphoma- Market Drivers and Barriers Hodgkin's Lymphoma- Future Perspectives and Conclusion Hodgkin's Lymphoma Analyst Views Hodgkin's Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Reuters
08-04-2025
- Business
- Reuters
Bristol Myers wins dismissal of lawsuit alleging Pomalyst monopoly
NEW YORK, April 8 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing sham patent lawsuits to maintain an illegal monopoly on its blockbuster blood cancer drug Pomalyst, keeping cheaper generic versions off the market. In a 70-page decision made public on Tuesday, U.S. District Judge Edgardo Ramos in Manhattan said the health insurer Blue Cross Blue Shield of Louisiana and other Pomalyst purchasers failed to show that Bristol Myers and the former Celgene Corp violated the federal Sherman antitrust law. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Ramos said the plaintiff purchasers failed to establish fraud in the procurement of six patents related to Pomalyst. He also said they failed to show how nine lawsuits that Celgene filed between 2017 and 2020 against generic drug producers such as Teva ( opens new tab and Mylan (VTRS.O), opens new tab were "objectively baseless" and led to fraudulent settlements. Lawyers for the plaintiffs did not immediately respond to requests for comment. The plaintiffs claimed they were overcharged for Pomalyst since at least October 2020, when generic versions of the multiple myeloma treatment allegedly could have been launched but for the defendants' alleged illegal scheme. Pomalyst sales totaled $3.55 billion in 2024, or about 7.3% of Bristol Myers' $48.3 billion of overall revenue. The drug was developed by Celgene, which Bristol Myers bought in 2019. Bristol Myers is based in Princeton, New Jersey. The case is Louisiana Health Service & Indemnity Co et al v Celgene Corp et al, U.S. District Court, Southern District of New York, No. 23-07871.
